EA Pharma Co. Ltd. has prepared and tested nitrogen-including heterocycle derivatives acting as 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors.
Work at Vivozon Inc. has led to the identification of dual metabotropic glutamate mGlu5 receptor antagonists and histone deacetylase 6 (HDAC6) inhibitors.
Pantetheinase (Vanin-1) inhibitors are described in an Athos Therapeutics Inc. patent as potentially useful for the treatment of autoimmune disease, cancer and inflammatory disorders.
University of Miami has patented new vasopressin V1A receptor antagonists reported to be useful for the treatment of osteoporosis, Paget disease and cancer.
Pancreatic cancer is among the most lethal cancers and the fourth leading cause of cancer deaths worldwide, where 90% of cases fall into the pancreatic ductal adenocarcinoma (PDAC) type.
Researchers from Southern Medical University and affiliated organizations presented the discovery and preclinical characterization of novel human urate transporter 1 (hURAT1) inhibitors being developed for the treatment of hyperuricemia.
EZH2 and LSD1 are histone modification enzymes often overexpressed in several types of aggressive cancer such as colorectal, breast or prostate cancer, among others.
Satellos Bioscience Inc. has developed and presented data for a compound that targeted the process of muscle regeneration based on modulation of satellite stem cell polarity.
RSS
